ALK and non-small cell lung carcinoma: Successfully applied drugs targeting BCR‐ABL1 fusion in hematological malignancy ALK fusion in NSCLC, have dramatically ignited enthusiasm for deep exploration of the landscape of gene fusions (Mertens et al., 2015).